Early switch from cladribine to alemtuzumab in highly-active relapsing-remitting multiple sclerosis: A case report
Neuroimmunology Reports
; 2 (no pagination), 2022.
Article
in English
| EMBASE | ID: covidwho-2299562
ABSTRACT
Background Management of patients with multiple sclerosis (MS) and evidence of disease activity during treatment with cladribine tablets represents a challenging point. Objectives To report a patient with highly active multiple sclerosis (HAMS) who has been early switched from cladribine to alemtuzumab owing to tumultuous clinical and radiological activity Methods A single retrospective case report. Results. Treatment with alemtuzumab has led to a complete suppression of disease activity without any evidence of infections or acquired autoimmune diseases. Conclusion Our report suggests that an early switch from cladribine to alemtuzumab, may be safe and efficacious in selected HAMS cases.Copyright © 2022 The Authors
Alemtuzumab; Case report; Cladribine; Multiple sclerosis; adult; arm disease; article; brain damage/di [Diagnosis]; brain region; cerebrospinal fluid examination; cervical spinal cord; clinical article; contrast enhancement; coronavirus disease 2019/dt [Drug Therapy]; coronavirus disease 2019/pc [Prevention]; diagnostic test; disease activity; dorsal root; drug megadose; drug substitution; drug withdrawal; dysarthria; evoked response; herpes zoster/dt [Drug Therapy]; herpes zoster/pc [Prevention]; human; human cell; laboratory test; leg disease; lymphocyte count; male; nuclear magnetic resonance imaging; paresthesia; pneumocystosis/dt [Drug Therapy]; pneumocystosis/pc [Prevention]; practice guideline; prognosis; relapsing remitting multiple sclerosis/dt [Drug Therapy]; retrospective study; skin tingling; symptom; tablet; treatment response; young adult; aciclovir/cb [Drug Combination]; aciclovir/dt [Drug Therapy]; alemtuzumab/dt [Drug Therapy]; cladribine/dt [Drug Therapy]; cotrimoxazole/cb [Drug Combination]; cotrimoxazole/do [Drug Dose]; cotrimoxazole/dt [Drug Therapy]; gadolinium; immunoglobulin G/ec [Endogenous Compound]; oligoclonal band/ec [Endogenous Compound]; steroid/do [Drug Dose]; steroid/dt [Drug Therapy]; steroid/iv [Intravenous Drug Administration]; tozinameran/dt [Drug Therapy]; unclassified drug; virus antibody/ec [Endogenous Compound]; JC virus antibody/ec [Endogenous Compound]
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Case report
Language:
English
Journal:
Neuroimmunology Reports
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS